Gemeenteraad eist snel duidelijkheid over komst nieuwe fabriek van Amerikaans farmaceutisch bedrijf #OmroepWest #Valkenburg #Katwijk #Farmaceut #Bedrijfsleven #EliLilly

https://owst.nl/5116992/M

Factbox: How to find and check an Ozempic batch number

https://web.brid.gy/r/https://interaksyon.philstar.com/rumor-cop/2026/06/02/282951/factbox-how-to-find-and-check-an-ozempic-batch-number/

Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial

#EliLilly #Retevmo #CancerResearch #ClinicalTrial
https://meyka.com/blog/eli-lilly-retevmo-cuts-cancer-recurrence-or-death-risk-by-83-in-phase-3-trial-of-151-nsclc-patients-2606/

Zorgen om veiligheid en verkeer door komst miljardenfabriek #OmroepWest #Katwijk #EliLilly #Fabrieken

https://owst.nl/5102587/M

US Top News and Analysis | Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

AI generated summary, Read the full article for complete information.

Bristol Myers Squibb announced a multi‑billion‑dollar partnership with China’s top drugmaker Hengrui Pharma to develop roughly a dozen new medicines, including four experimental compounds that BMS will send to China for early‑stage clinical testing. Unlike typical licensing deals where U.S. firms outsource Chinese discoveries, this reciprocal arrangement has both companies contributing assets and jointly discovering novel drugs, signaling a shift toward a “global mesh” model of R&D. Industry observers note that American and European biopharma firms are increasingly turning to China for faster, cheaper early‑stage research—potentially cutting development time by half and costs by two‑thirds—while later‑stage trials remain U.S.‑centric to satisfy FDA requirements. The deal underscores China’s growing role as a central hub in global drug development rather than merely a source of one‑off molecules.

Read more: https://www.cnbc.com/2026/05/15/bristol-myers-squibb-turns-to-chinas-hengrui-to-replenish-pipeline.html

#BristolMyers #HengruiPharma #Pfizer #Merck #AstraZeneca #EliLilly #MichaelBaran #McKinsey #DealForma #FDA # #LievenVanderVeken

Wall Street Journal: The quest to use AI to help find new drugs. “Lilly first announced a partnership with chip-maker Nvidia in October to build what it called the industry’s most powerful supercomputer, and expanded that in January with a $1 billion, five-year collaboration mixing their scientists and engineers in a new Bay Area lab aimed at discovering new medicines with AI tools. They […]

‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s

https://fed.brid.gy/r/https://globalnews.ca/news/11828976/health-canada-second-drug-alzheimers/

US Top News and Analysis | Stocks making the biggest moves midday: Qualcomm, Hertz, Eli Lilly, Meta Platforms, Microsoft & more

AI generated summary, Read the full article for complete information.

Midday trading saw a mix of sharp gains and losses across major U.S. equities as companies released first‑quarter results and strategic updates. Blue Owl Capital surged nearly 10% after announcing a 10‑times return on its SpaceX investment, while Willis Towers Watson fell about 12% on slower‑than‑expected organic revenue growth. Hertz’s shares jumped roughly 18% following a partnership with Uber to develop autonomous robotaxi services, and Altria rose over 5% after beating earnings expectations and reaffirming its full‑year guidance. Carrier Global gained 11% on a strong earnings beat, whereas Meta Platforms dropped 9% despite solid quarterly results because it lifted its full‑year capital‑expenditure outlook, sparking AI‑spending concerns. Eli Lilly advanced 9% after surpassing earnings and revenue forecasts and raising its sales outlook, and Alphabet climbed 7% on a revenue beat driven by a 63% jump in Google Cloud. Microsoft slipped 5% after reporting capital‑expenditure figures below forecasts, while Royal Caribbean, Caterpillar, Amazon, Qualcomm and several consumer names (Chipotle, Sprouts, Wyndham) posted notable moves tied to earnings beats, guidance upgrades, or product milestones. The roundup highlights how earnings surprises, strategic partnerships, and forward‑looking guidance continue to drive short‑term market volatility.

Read more: https://www.cnbc.com/2026/04/30/stocks-making-the-biggest-moves-midday-qcom-htz-lly-meta-msft.html

#Qualcomm #HertzGlobal #EliLilly #MetaPlatforms #Microsoft #BlueOwlCapital #WillisTowersWatson #AltriaGroup #CarrierGlobal #Alphabet #

US Top News and Analysis | Jim Cramer's top 10 things to watch in the stock market Thursday

AI generated summary, Read the full article for complete information.

On Thursday, April 30 2026, Jim Cramer highlighted ten market catalysts: Alphabet topped earnings with strong AI‑driven growth in search, subscriptions and cloud, prompting a price‑target hike to $400; Amazon followed, boosting AWS to 28% growth and maintaining a $200 billion capex plan, lifting its target to $300; Microsoft saw 40% cloud growth and Copilot expansion, keeping its $500 target despite a slight stock dip; Meta’s lack of a cloud business hurt sentiment, leading to an 8.5% share decline and a reduced target of $750; broader market forces—robust earnings, lower oil, and bond yields—should support a higher S&P 500 opening; Eli Lilly smashed forecasts with a 49% U.S. volume surge, sending its stock up over 6%; Cardinal Health delivered modest earnings improvement but fell 1%; AI start‑up Anthropic is in talks for a $900 billion valuation; Qualcomm’s data‑center chip launch for a “large hyperscaler” spurred a >10% rally; and Intel, riding soaring demand for AI chips, hit an all‑time high with shares jumping nearly 24% after blockbuster earnings.

Read more: https://www.cnbc.com/2026/04/30/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html

#JimCramer #JeromePowell #Alphabet #Amazon #EliLilly #AndyJassy #DavidRicks